{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:36:26Z","timestamp":1792787786448,"version":"4.5.0"},"reference-count":46,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Aurealis Oy"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Endocrinology"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Diabetic foot ulcer (DFU) is a common and highly morbid complication of diabetes with high unmet medical needs. AUP1602-C, a topical four-in-one gene therapy medicinal product (GTMP), consisting of a Lactococcus cremoris strain that produces fibroblast growth factor-2, interleukin-4, and colony-stimulating factor-1, is a promising novel treatment for DFU.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>The aim of this first-in-human study was to investigate whether AUP1602-C is safe and effective in improving wound healing and quality of life (QoL) in patients with non-healing DFU (nhDFU), and to determine the recommended phase II dose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Phase I, single-arm, open-label, uncontrolled, dose escalation study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      The study consisted of four cohorts of patients receiving AUP1602-C as a single dose of 2.5\u2009\u00d7\u200910\n                      <jats:sup>5<\/jats:sup>\n                      colony-forming units (CFU)\/cm\n                      <jats:sup>2<\/jats:sup>\n                      ulcer size or as repeated doses between 2.5\u2009\u00d7\u200910\n                      <jats:sup>6<\/jats:sup>\n                      and 2.5\u2009\u00d7\u200910\n                      <jats:sup>8<\/jats:sup>\n                      \u2009CFU\/cm\n                      <jats:sup>2<\/jats:sup>\n                      administered 3 times per week for 6\u2009weeks. Within each cohort, a 3\u2009+\u20093 scheme for monitoring safety, tolerability, and efficacy was applied.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      In total, 16 patients aged 53\u201380\u2009years were included, 3 each in the safety and low dose, 4 in the medium dose, and 6 in the high-dose cohort. AUP1602-C demonstrated a favorable safety profile with almost 100% dosing compliance. The most frequently reported side effect related to treatment was skin maceration. No serious adverse reactions, systemic toxicity, deaths, or side effects suggestive of immunogenicity, hypersensitivity, allergic reaction, or dose-limiting toxicities related to treatment were reported. No biodistribution events were observed and shedding-related events were rare and did neither show accumulation nor dose dependency. The recommended phase II dose of 2.5\u2009\u00d7\u200910\n                      <jats:sup>8<\/jats:sup>\n                      \u2009CFU\/cm\n                      <jats:sup>2<\/jats:sup>\n                      demonstrated complete healing in 83% of patients without recurrence of ulcers during follow-up.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>AUP1602-C was safe and well tolerated and demonstrated dose-dependent efficacy in patients with nhDFU. Data supports further clinical development of AUP1602-C.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration:<\/jats:title>\n                    <jats:p>The study was registered in ClinicalTrials.gov (NCT04281992) and ClinicalTrialsRegister.eu (2018-003415-22).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20420188241294134","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T06:43:38Z","timestamp":1730702618000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":14,"title":["Multi-target gene therapy AUP1602-C to improve healing and quality of life for diabetic foot ulcer patients: a phase I, open-label, dose-finding study"],"prefix":"10.1177","volume":"15","author":[{"given":"Christoph","family":"Schindler","sequence":"first","affiliation":[{"name":"Center for Clinical Trials and Center for Pharmacology and Toxicology, Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Mikosi\u0144ski","sequence":"additional","affiliation":[{"name":"MIKOMED Sp., Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Mikosi\u0144ski","sequence":"additional","affiliation":[{"name":"MIKOMED Sp., Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna-Riikka","family":"K\u00e4rkk\u00e4inen","sequence":"additional","affiliation":[{"name":"Aurealis Therapeutics, Zug, Switzerland"},{"name":"Aurealis Therapeutics, Kuopio, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirka","family":"Sanio","sequence":"additional","affiliation":[{"name":"Aurealis Therapeutics, Zug, Switzerland"},{"name":"Aurealis Therapeutics, Kuopio, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jere","family":"Kurkipuro","sequence":"additional","affiliation":[{"name":"Aurealis Therapeutics, Zug, Switzerland"},{"name":"Aurealis Therapeutics, Kuopio, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Mierau","sequence":"additional","affiliation":[{"name":"Aurealis Therapeutics, Zug, Switzerland"},{"name":"Aurealis Therapeutics, Kuopio, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley","family":"Smith","sequence":"additional","affiliation":[{"name":"Aurealis Therapeutics, Zug, Switzerland"},{"name":"Aurealis Therapeutics, Kuopio, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aki","family":"Vartiainen","sequence":"additional","affiliation":[{"name":"Aurealis Therapeutics, Zug, Switzerland"},{"name":"Aurealis Therapeutics, Kuopio, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"D\u00e9cory","sequence":"additional","affiliation":[{"name":"Aurealis Therapeutics, Zug, Switzerland"},{"name":"Aurealis Therapeutics, Kuopio, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Weber","sequence":"additional","affiliation":[{"name":"Aurealis Therapeutics, Zug, Switzerland"},{"name":"Aurealis Therapeutics, Kuopio, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wirth","sequence":"additional","affiliation":[{"name":"Aurealis Therapeutics, Zug, Switzerland"},{"name":"Aurealis Therapeutics, Kuopio, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juha","family":"Yrj\u00e4nheikki","sequence":"additional","affiliation":[{"name":"Aurealis Therapeutics, Zug, Switzerland"},{"name":"Aurealis Therapeutics, Kuopio, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Schellong","sequence":"additional","affiliation":[{"name":"St\u00e4dtisches Klinikum Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7009-1671","authenticated-orcid":false,"given":"Haritha","family":"Samaranayake","sequence":"additional","affiliation":[{"name":"Aurealis Therapeutics, Microkatu 1, Kuopio 70210, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,11,4]]},"reference":[{"key":"bibr1-20420188241294134","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109119"},{"key":"bibr2-20420188241294134","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0043"},{"key":"bibr3-20420188241294134","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.10578"},{"key":"bibr4-20420188241294134","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0536"},{"key":"bibr5-20420188241294134","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9061780"},{"key":"bibr6-20420188241294134","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13054"},{"key":"bibr7-20420188241294134","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1615439"},{"key":"bibr8-20420188241294134","doi-asserted-by":"publisher","DOI":"10.1007\/s12262-010-0005-8"},{"key":"bibr9-20420188241294134","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-2189"},{"key":"bibr10-20420188241294134","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-006-0491-1"},{"key":"bibr11-20420188241294134","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2176"},{"key":"bibr12-20420188241294134","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3644"},{"key":"bibr13-20420188241294134","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.22.5.692"},{"key":"bibr14-20420188241294134","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12564"},{"key":"bibr15-20420188241294134","doi-asserted-by":"publisher","DOI":"10.1111\/iwj.12816"},{"key":"bibr16-20420188241294134","doi-asserted-by":"publisher","DOI":"10.1089\/wound.2017.0743"},{"key":"bibr17-20420188241294134","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67695-7"},{"key":"bibr18-20420188241294134","doi-asserted-by":"publisher","DOI":"10.2337\/dc07-2196"},{"key":"bibr19-20420188241294134","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmrj.2009.03.012"},{"key":"bibr20-20420188241294134","unstructured":"U.S. Food & Drug administration. FDA permits marketing of device to treat diabetic foot ulcers, https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-permits-marketing-device-treat-diabetic-foot-ulcers (2017, accessed 5 July 2024)."},{"issue":"6","key":"bibr21-20420188241294134","volume":"45","author":"Thomas DR","year":"1999","journal-title":"Ostomy Wound Manage"},{"issue":"3","key":"bibr22-20420188241294134","first-page":"223","volume":"28","author":"Lalau JD","year":"2002","journal-title":"Diabetes Metab"},{"issue":"50","key":"bibr23-20420188241294134","first-page":"5755","volume":"95","author":"Michanek A","year":"1998","journal-title":"Lakartidningen"},{"issue":"2","key":"bibr24-20420188241294134","volume":"2","author":"Santema TB","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"bibr25-20420188241294134","volume":"2015","author":"Marti-Carvajal AJ","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr26-20420188241294134","doi-asserted-by":"publisher","DOI":"10.3390\/genes5040926"},{"key":"bibr27-20420188241294134","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13954"},{"key":"bibr28-20420188241294134","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17122085"},{"key":"bibr29-20420188241294134","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.1998.00381.x"},{"key":"bibr30-20420188241294134","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2018.00419"},{"key":"bibr31-20420188241294134","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0264775"},{"key":"bibr32-20420188241294134","doi-asserted-by":"publisher","DOI":"10.3109\/07853890109002087"},{"key":"bibr33-20420188241294134","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.02.008"},{"key":"bibr34-20420188241294134","unstructured":"Cardiff University School of Medicine. Dermatology life quality index, https:\/\/www.cardiff.ac.uk\/medicine\/resources\/quality-of-life-questionnaires\/dermatology-life-quality-index (1994)."},{"key":"bibr35-20420188241294134","unstructured":"International Working Group on the Diabetic Foot. All IWGDF guidelines (2019 update), https:\/\/iwgdfguidelines.org\/guidelines-2019\/guidelines-2019\/ (2019, accessed 15 July 2024)."},{"key":"bibr36-20420188241294134","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.21.5.855"},{"key":"bibr37-20420188241294134","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9610(98)00185-8"},{"key":"bibr38-20420188241294134","doi-asserted-by":"publisher","DOI":"10.1097\/01.sap.0000198731.12407.0c"},{"key":"bibr39-20420188241294134","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-481X.2008.00561.x"},{"key":"bibr40-20420188241294134","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2007.06.004"},{"key":"bibr41-20420188241294134","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.24.2.290"},{"key":"bibr42-20420188241294134","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.6.1701"},{"key":"bibr43-20420188241294134","doi-asserted-by":"publisher","DOI":"10.1111\/wrr.12357"},{"key":"bibr44-20420188241294134","doi-asserted-by":"publisher","DOI":"10.1046\/j.1524-475X.2001.00258.x"},{"key":"bibr45-20420188241294134","unstructured":"FDA. Guidance for industry: chronic cutaneous ulcer and burn wounds\u2014developing products for treatment, http:\/\/www.fda.gov\/media\/71278\/download (2006, accessed 15 July 2024)."},{"key":"bibr46-20420188241294134","doi-asserted-by":"publisher","DOI":"10.3390\/s23094423"}],"container-title":["Therapeutic Advances in Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20420188241294134","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20420188241294134","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20420188241294134","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:36:41Z","timestamp":1777592201000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20420188241294134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":46,"alternative-id":["10.1177\/20420188241294134"],"URL":"https:\/\/doi.org\/10.1177\/20420188241294134","relation":{},"ISSN":["2042-0188","2042-0196"],"issn-type":[{"value":"2042-0188","type":"print"},{"value":"2042-0196","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5]]},"article-number":"20420188241294134"}}